{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:05:15Z","timestamp":1786460715878,"version":"build-2736575974"},"reference-count":259,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01178-z","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:33:41Z","timestamp":1786448021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unconventional T cells in urological cancers: catch them if you can"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-2839","authenticated-orcid":false,"given":"Amber D.","family":"Bowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-9464","authenticated-orcid":false,"given":"Sonia","family":"Domingos-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Lucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-161X","authenticated-orcid":false,"given":"Laurent","family":"Derr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"1178_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1178_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148\u2013163 (2024).","journal-title":"Eur. Urol."},{"key":"1178_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.urology.2023.10.018","volume":"184","author":"KD Stensland","year":"2024","unstructured":"Stensland, K. D. et al. National long-term survival estimates after radical prostatectomy for prostate cancer. Urology 184, 135\u2013141 (2024).","journal-title":"Urology"},{"key":"1178_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero, P. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2014 a summary of the 2024 guidelines update. Eur. Urol. 86, 531\u2013549 (2024).","journal-title":"Eur. Urol."},{"key":"1178_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden, A. G. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur. Urol. 87, 582\u2013600 (2025).","journal-title":"Eur. Urol."},{"key":"1178_CR6","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/ijc.35077","volume":"155","author":"F Di Bello","year":"2024","unstructured":"Di Bello, F. et al. Contemporary survival in metastatic bladder cancer patients: a population-based study. Int. J. Cancer 155, 1762\u20131768 (2024).","journal-title":"Int. J. Cancer"},{"key":"1178_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young, M. et al. Renal cell carcinoma. Lancet 404, 476\u2013491 (2024).","journal-title":"Lancet"},{"key":"1178_CR8","first-page":"273","volume":"53","author":"P Ehrlich","year":"1909","unstructured":"Ehrlich, P. \u00dcber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 53, 273\u2013290 (1909).","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"1178_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"1178_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"1178_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Sautes-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1178_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.immuni.2018.03.009","volume":"48","author":"DI Godfrey","year":"2018","unstructured":"Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P. & Rossjohn, J. Unconventional T cell targets for cancer immunotherapy. Immunity 48, 453\u2013473 (2018).","journal-title":"Immunity"},{"key":"1178_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","volume":"32","author":"YH Chien","year":"2014","unstructured":"Chien, Y. H., Meyer, C. & Bonneville, M. \u03b3\u03b4 T cells: first line of defense and beyond. Annu. Rev. Immunol. 32, 121\u2013155 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"1178_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn3954","volume":"9","author":"JI Gray","year":"2024","unstructured":"Gray, J. I. et al. Human \u03b3\u03b4 T cells in diverse tissues exhibit site-specific maturation dynamics across the life span. Sci. Immunol. 9, eadn3954 (2024).","journal-title":"Sci. Immunol."},{"key":"1178_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.168.2.491","volume":"168","author":"C Bottino","year":"1988","unstructured":"Bottino, C. et al. Two subsets of human T lymphocytes expressing gamma\/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor. J. Exp. Med. 168, 491\u2013505 (1988).","journal-title":"J. Exp. Med."},{"key":"1178_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/325689a0","volume":"325","author":"MB Brenner","year":"1987","unstructured":"Brenner, M. B. et al. Two forms of the T-cell receptor \u03b3 protein found on peripheral blood cytotoxic T lymphocytes. Nature 325, 689\u2013694 (1987).","journal-title":"Nature"},{"key":"1178_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clim.2004.05.003","volume":"113","author":"T Kenna","year":"2004","unstructured":"Kenna, T. et al. Distinct subpopulations of \u03b3\u03b4 T cells are present in normal and tumor-bearing human liver. Clin. Immunol. 113, 56\u201363 (2004).","journal-title":"Clin. Immunol."},{"key":"1178_CR18","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1084\/jem.171.5.1597","volume":"171","author":"CM Parker","year":"1990","unstructured":"Parker, C. M. et al. Evidence for extrathymic changes in the T cell receptor gamma\/delta repertoire. J. Exp. Med. 171, 1597\u20131612 (1990).","journal-title":"J. Exp. Med."},{"key":"1178_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/BF00172178","volume":"42","author":"SP Clark","year":"1995","unstructured":"Clark, S. P., Arden, B., Kabelitz, D. & Mak, T. W. Comparison of human and mouse T-cell receptor variable gene segment subfamilies. Immunogenetics 42, 531\u2013540 (1995).","journal-title":"Immunogenetics"},{"key":"1178_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00251-014-0763-8","volume":"66","author":"MM Karunakaran","year":"2014","unstructured":"Karunakaran, M. M., Gobel, T. W., Starick, L., Walter, L. & Herrmann, T. V\u03b39 and V\u03b42 T cell antigen receptor genes and butyrophilin 3 (BTN3) emerged with placental mammals and are concomitantly preserved in selected species like alpaca (Vicugna pacos). Immunogenetics 66, 243\u2013254 (2014).","journal-title":"Immunogenetics"},{"key":"1178_CR21","doi-asserted-by":"publisher","first-page":"E332","DOI":"10.1073\/pnas.1105105108","volume":"108","author":"AR Kazen","year":"2011","unstructured":"Kazen, A. R. & Adams, E. J. Evolution of the V, D, and J gene segments used in the primate \u03b3\u03b4 T-cell receptor reveals a dichotomy of conservation and diversity. Proc. Natl Acad. Sci. USA 108, E332\u2013E340 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1178_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41590-020-00848-3","volume":"22","author":"N Lopes","year":"2021","unstructured":"Lopes, N. et al. Distinct metabolic programs established in the thymus control effector functions of \u03b3\u03b4 T cell subsets in tumor microenvironments. Nat. Immunol. 22, 179\u2013192 (2021).","journal-title":"Nat. Immunol."},{"key":"1178_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI193945","author":"Y Deng","year":"2025","unstructured":"Deng, Y. et al. IL-17-producing \u03b3\u03b4 T cells in the tumor microenvironment promote radioresistance in mice. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI193945 (2025).","journal-title":"J. Clin. Invest."},{"key":"1178_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2026.116977","volume":"45","author":"C La","year":"2026","unstructured":"La, C. et al. In vivo modeling of human \u03b3\u03b4 T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 V\u03b42 T cell development. Cell Rep. 45, 116977 (2026).","journal-title":"Cell Rep."},{"key":"1178_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003501","volume":"9","author":"CY Chen","year":"2013","unstructured":"Chen, C. Y. et al. Phosphoantigen\/IL2 expansion and differentiation of V\u03b32V\u03b42 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog. 9, e1003501 (2013).","journal-title":"PLoS Pathog."},{"key":"1178_CR26","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.4049\/jimmunol.170.7.3696","volume":"170","author":"H Wang","year":"2003","unstructured":"Wang, H. et al. Conservation of nonpeptide antigen recognition by rhesus monkey V\u03b32V\u03b42 T cells. J. Immunol. 170, 3696\u20133706 (2003).","journal-title":"J. Immunol."},{"key":"1178_CR27","doi-asserted-by":"publisher","first-page":"6697","DOI":"10.1073\/pnas.1909474117","volume":"117","author":"AS Fichtner","year":"2020","unstructured":"Fichtner, A. S. et al. Alpaca (Vicugna pacos), the first nonprimate species with a phosphoantigen-reactive V\u03b32V\u03b42 T cell subset. Proc. Natl Acad. Sci. USA 117, 6697\u20136707 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1178_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/0923-2494(96)89648-9","volume":"147","author":"JJ Fournie","year":"1996","unstructured":"Fournie, J. J. & Bonneville, M. Stimulation of \u03b3\u03b4 T cells by phosphoantigens. Res. Immunol. 147, 338\u2013347 (1996).","journal-title":"Res. Immunol."},{"key":"1178_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/1074-7613(95)90178-7","volume":"3","author":"CT Morita","year":"1995","unstructured":"Morita, C. T. et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human \u03b3\u03b4 T cells. Immunity 3, 495\u2013507 (1995).","journal-title":"Immunity"},{"key":"1178_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jaci.2014.12.1937","volume":"136","author":"O Ardeniz","year":"2015","unstructured":"Ardeniz, O. et al. \u03b22-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system. J. Allergy Clin. Immunol. 136, 392\u2013401 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1178_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jaci.2024.06.003","volume":"154","author":"A Elsayed","year":"2024","unstructured":"Elsayed, A. et al. Phenotypic and pathomechanistic overlap between tapasin and TAP deficiencies. J. Allergy Clin. Immunol. 154, 1069\u20131075 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1178_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/341447a0","volume":"341","author":"S Porcelli","year":"1989","unstructured":"Porcelli, S. et al. Recognition of cluster of differentiation 1 antigens by human CD4\u2212CD8\u2212 cytolytic T lymphocyte. Nature 341, 447\u2013450 (1989).","journal-title":"Nature"},{"key":"1178_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/360593a0","volume":"360","author":"S Porcelli","year":"1992","unstructured":"Porcelli, S., Morita, C. T. & Brenner, M. B. CD1b restricts the response of human CD4\u22128\u2212 T lymphocytes to a microbial antigen. Nature 360, 593\u2013597 (1992).","journal-title":"Nature"},{"key":"1178_CR34","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.4049\/jimmunol.178.6.3620","volume":"178","author":"AM Russano","year":"2007","unstructured":"Russano, A. M. et al. CD1-restricted recognition of exogenous and self-lipid antigens by duodenal \u03b3\u03b4+ T lymphocytes. J. Immunol. 178, 3620\u20133626 (2007).","journal-title":"J. Immunol."},{"key":"1178_CR35","doi-asserted-by":"publisher","first-page":"22944","DOI":"10.1073\/pnas.2010545117","volume":"117","author":"JF Reijneveld","year":"2020","unstructured":"Reijneveld, J. F. et al. Human \u03b3\u03b4 T cells recognize CD1b by two distinct mechanisms. Proc. Natl Acad. Sci. USA 117, 22944\u201322952 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1178_CR36","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1126\/science.aav3900","volume":"366","author":"J Le Nours","year":"2019","unstructured":"Le Nours, J. et al. A class of \u03b3\u03b4 T cell receptors recognize the underside of the antigen-presenting molecule MR1. Science 366, 1522\u20131527 (2019).","journal-title":"Science"},{"key":"1178_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba9010","volume":"6","author":"C Harly","year":"2021","unstructured":"Harly, C. et al. Human \u03b3\u03b4 T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2. Sci. Immunol. 6, eaba9010 (2021).","journal-title":"Sci. Immunol."},{"key":"1178_CR38","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1084\/jem.171.5.1567","volume":"171","author":"P Fisch","year":"1990","unstructured":"Fisch, P. et al. Gamma\/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J. Exp. Med. 171, 1567\u20131579 (1990).","journal-title":"J. Exp. Med."},{"key":"1178_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/375155a0","volume":"375","author":"Y Tanaka","year":"1995","unstructured":"Tanaka, Y. et al. Natural and synthetic non-peptide antigens recognized by human \u03b3\u03b4 T cells. Nature 375, 155\u2013158 (1995).","journal-title":"Nature"},{"key":"1178_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0014-5793(03)00483-6","volume":"544","author":"M Eberl","year":"2003","unstructured":"Eberl, M. et al. Microbial isoprenoid biosynthesis and human \u03b3\u03b4 T cell activation. FEBS Lett. 544, 4\u201310 (2003).","journal-title":"FEBS Lett."},{"key":"1178_CR41","doi-asserted-by":"publisher","first-page":"13172","DOI":"10.1073\/pnas.240454797","volume":"97","author":"BM Lange","year":"2000","unstructured":"Lange, B. M., Rujan, T., Martin, W. & Croteau, R. Isoprenoid biosynthesis: the evolution of two ancient and distinct pathways across genomes. Proc. Natl Acad. Sci. USA 97, 13172\u201313177 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1178_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"HJ Gober","year":"2003","unstructured":"Gober, H. J. et al. Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163\u2013168 (2003).","journal-title":"J. Exp. Med."},{"key":"1178_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0014-5793(01)03191-X","volume":"509","author":"M Hintz","year":"2001","unstructured":"Hintz, M. et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human \u03b3\u03b4 T cells in Escherichia coli. FEBS Lett. 509, 317\u2013322 (2001).","journal-title":"FEBS Lett."},{"key":"1178_CR44","first-page":"371","volume":"25","author":"H Jomaa","year":"1999","unstructured":"Jomaa, H. et al. V\u03b39\/V\u03b42 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunol. Med. Microbiol. 25, 371\u2013378 (1999).","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"1178_CR45","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0960-894X(03)00138-0","volume":"13","author":"A Reichenberg","year":"2003","unstructured":"Reichenberg, A. et al. Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates its potential to activate human \u03b3\u03b4 T cells but does not lead to competitive antagonism. Bioorg. Med. Chem. Lett. 13, 1257\u20131260 (2003).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1178_CR46","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.immuni.2025.05.011","volume":"58","author":"M Zhang","year":"2025","unstructured":"Zhang, M. et al. Structures of butyrophilin multimers reveal a plier-like mechanism for V \u03b39V\u03b42 T cell receptor activation. Immunity 58, 1660\u20131669.e7 (2025).","journal-title":"Immunity"},{"key":"1178_CR47","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.immuni.2025.04.012","volume":"58","author":"Y Zhu","year":"2025","unstructured":"Zhu, Y. et al. Phosphoantigen-induced inside-out stabilization of butyrophilin receptor complexes drives dimerization-dependent gammadelta TCR activation. Immunity 58, 1646\u20131659.e5 (2025).","journal-title":"Immunity"},{"key":"1178_CR48","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41423-020-0503-y","volume":"17","author":"M Deseke","year":"2020","unstructured":"Deseke, M. & Prinz, I. Ligand recognition by the \u03b3\u03b4 TCR and discrimination between homeostasis and stress conditions. Cell Mol. Immunol. 17, 914\u2013924 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"1178_CR49","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ni.2394","volume":"13","author":"CR Willcox","year":"2012","unstructured":"Willcox, C. R. et al. Cytomegalovirus and tumor stress surveillance by binding of a human \u03b3\u03b4 T cell antigen receptor to endothelial protein C receptor. Nat. Immunol. 13, 872\u2013879 (2012).","journal-title":"Nat. Immunol."},{"key":"1178_CR50","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1073\/pnas.1621052114","volume":"114","author":"R Marlin","year":"2017","unstructured":"Marlin, R. et al. Sensing of cell stress by human \u03b3\u03b4 TCR-dependent recognition of annexin A2. Proc. Natl Acad. Sci. USA 114, 3163\u20133168 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1178_CR51","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727\u2013729 (1999).","journal-title":"Science"},{"key":"1178_CR52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1074-7613(01)00168-6","volume":"15","author":"H Das","year":"2001","unstructured":"Das, H. et al. MICA engagement by human V\u03b32V\u03b42 T cells enhances their antigen-dependent effector function. Immunity 15, 83\u201393 (2001).","journal-title":"Immunity"},{"key":"1178_CR53","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1126\/science.279.5357.1737","volume":"279","author":"V Groh","year":"1998","unstructured":"Groh, V., Steinle, A., Bauer, S. & Spies, T. Recognition of stress-induced MHC molecules by intestinal epithelial \u03b3\u03b4 T cells. Science 279, 1737\u20131740 (1998).","journal-title":"Science"},{"key":"1178_CR54","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2008-12-196287","volume":"114","author":"Y Kong","year":"2009","unstructured":"Kong, Y. et al. The NKG2D ligand ULBP4 binds to TCR\u03b39\/\u03b42 and induces cytotoxicity to tumor cells through both TCR\u03b3\u03b4 and NKG2D. Blood 114, 310\u2013317 (2009).","journal-title":"Blood"},{"key":"1178_CR55","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22892","volume":"2","author":"DV Correia","year":"2013","unstructured":"Correia, D. V., Lopes, A. & Silva-Santos, B. Tumor cell recognition by \u03b3\u03b4 T lymphocytes: T-cell receptor vs. NK-cell receptors. Oncoimmunology 2, e22892 (2013).","journal-title":"Oncoimmunology"},{"key":"1178_CR56","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s00018-011-0698-2","volume":"68","author":"JC Ribot","year":"2011","unstructured":"Ribot, J. C., debarros, A. & Silva-Santos, B. Searching for \u201csignal 2\u201d: costimulation requirements of \u03b3\u03b4 T cells. Cell Mol. Life Sci. 68, 2345\u20132355 (2011).","journal-title":"Cell Mol. Life Sci."},{"key":"1178_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgaf358","volume":"4","author":"D Gombert","year":"2025","unstructured":"Gombert, D. et al. Butyrophilin 3A\/2A1-independent activation of human V\u03b39V\u03b42 \u03b3\u03b4 T cells by bacteria. PNAS Nexus 4, pgaf358 (2025).","journal-title":"PNAS Nexus"},{"key":"1178_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01868","volume":"11","author":"P Aehnlich","year":"2020","unstructured":"Aehnlich, P., Carnaz Simoes, A. M., Skadborg, S. K., Holmen Olofsson, G. & Thor Straten, P. Expansion with IL-15 increases cytotoxicity of V\u03b39V\u03b42 T cells and is associated with higher levels of cytotoxic molecules and T-bet. Front. Immunol. 11, 1868 (2020).","journal-title":"Front. Immunol."},{"key":"1178_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010130","volume":"12","author":"K Schilbach","year":"2020","unstructured":"Schilbach, K. et al. In the absence of a TCR signal IL-2\/IL-12\/18-stimulated \u03b3\u03b4 T cells demonstrate potent anti-tumoral function through direct killing and senescence induction in cancer cells. Cancers 12, 130 (2020).","journal-title":"Cancers"},{"key":"1178_CR60","doi-asserted-by":"publisher","first-page":"45928","DOI":"10.18632\/oncotarget.17498","volume":"8","author":"E Domae","year":"2017","unstructured":"Domae, E., Hirai, Y., Ikeo, T., Goda, S. & Shimizu, Y. Cytokine-mediated activation of human ex vivo-expanded V\u03b39V\u03b42 T cells. Oncotarget 8, 45928\u201345942 (2017).","journal-title":"Oncotarget"},{"key":"1178_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/imr.12904","volume":"298","author":"E Lo Presti","year":"2020","unstructured":"Lo Presti, E., Dieli, F., Fournie, J. J. & Meraviglia, S. Deciphering human \u03b3\u03b4 T cell response in cancer: lessons from tumor-infiltrating \u03b3\u03b4 T cells. Immunol. Rev. 298, 153\u2013164 (2020).","journal-title":"Immunol. Rev."},{"key":"1178_CR62","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado, S., Blanco-Dominguez, R. & Silva-Santos, B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178\u2013191 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1178_CR63","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/JLB.5MA1119-265R","volume":"107","author":"HH Oberg","year":"2020","unstructured":"Oberg, H. H. et al. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. J. Leukoc. Biol. 107, 1081\u20131095 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"1178_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148988","volume":"14","author":"M Sanz","year":"2023","unstructured":"Sanz, M. et al. Deep characterization of human \u03b3\u03b4 T cell subsets defines shared and lineage-specific traits. Front. Immunol. 14, 1148988 (2023).","journal-title":"Front. Immunol."},{"key":"1178_CR65","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","volume":"184","author":"M D\u2019Asaro","year":"2010","unstructured":"D\u2019Asaro, M. et al. V\u03b39V\u03b42 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J. Immunol. 184, 3260\u20133268 (2010).","journal-title":"J. Immunol."},{"key":"1178_CR66","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1002\/eji.201243150","volume":"43","author":"P Dokouhaki","year":"2013","unstructured":"Dokouhaki, P. et al. NKG2D regulates production of soluble TRAIL by ex vivo expanded human \u03b3\u03b4 T cells. Eur. J. Immunol. 43, 3175\u20133182 (2013).","journal-title":"Eur. J. Immunol."},{"key":"1178_CR67","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.intimp.2011.01.001","volume":"11","author":"Z Li","year":"2011","unstructured":"Li, Z. et al. IFN-\u03b3 enhances HOS and U2OS cell lines susceptibility to \u03b3\u03b4 T cell-mediated killing through the Fas\/Fas ligand pathway. Int. Immunopharmacol. 11, 496\u2013503 (2011).","journal-title":"Int. Immunopharmacol."},{"key":"1178_CR68","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2004-01-0331","volume":"104","author":"DF Angelini","year":"2004","unstructured":"Angelini, D. F. et al. Fc\u03b3\u03b4RIII discriminates between 2 subsets of V\u03b39V\u03b42 effector cells with different responses and activation pathways. Blood 104, 1801\u20131807 (2004).","journal-title":"Blood"},{"key":"1178_CR69","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4049\/jimmunol.1102654","volume":"188","author":"N Himoudi","year":"2012","unstructured":"Himoudi, N. et al. Human gammadelta T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J. Immunol. 188, 1708\u20131716 (2012).","journal-title":"J. Immunol."},{"key":"1178_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1347742","volume":"6","author":"S Meraviglia","year":"2017","unstructured":"Meraviglia, S. et al. Distinctive features of tumor-infiltrating \u03b3\u03b4 T lymphocytes in human colorectal cancer. Oncoimmunology 6, e1347742 (2017).","journal-title":"Oncoimmunology"},{"key":"1178_CR71","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.4049\/jimmunol.1303119","volume":"192","author":"JC Ribot","year":"2014","unstructured":"Ribot, J. C., Ribeiro, S. T., Correia, D. V., Sousa, A. E. & Silva-Santos, B. Human \u03b3\u03b4 thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2\/IL-15 signaling. J. Immunol. 192, 2237\u20132243 (2014).","journal-title":"J. Immunol."},{"key":"1178_CR72","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.it.2006.01.002","volume":"27","author":"B Moser","year":"2006","unstructured":"Moser, B. & Brandes, M. \u03b3\u03b4 T cells: an alternative type of professional APC. Trends Immunol. 27, 112\u2013118 (2006).","journal-title":"Trends Immunol."},{"key":"1178_CR73","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s43018-025-00948-9","volume":"6","author":"R Blanco-Dominguez","year":"2025","unstructured":"Blanco-Dominguez, R. et al. Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer. Nat. Cancer 6, 1056\u20131072 (2025).","journal-title":"Nat. Cancer"},{"key":"1178_CR74","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s43018-023-00589-w","volume":"4","author":"C Harmon","year":"2023","unstructured":"Harmon, C. et al. \u03b3\u03b4 T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors. Nat. Cancer 4, 1122\u20131137 (2023).","journal-title":"Nat. Cancer"},{"key":"1178_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00508","volume":"8","author":"B Castella","year":"2018","unstructured":"Castella, B., Melaccio, A., Foglietta, M., Riganti, C. & Massaia, M. V\u03b39V\u03b42 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma. Front. Oncol. 8, 508 (2018).","journal-title":"Front. Oncol."},{"key":"1178_CR76","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/ijc.34669","volume":"153","author":"L Yu","year":"2023","unstructured":"Yu, L. et al. Tumor-infiltrating gamma delta T-cells reveal exhausted subsets with remarkable heterogeneity in colorectal cancer. Int. J. Cancer 153, 1684\u20131697 (2023).","journal-title":"Int. J. Cancer"},{"key":"1178_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29012-1","volume":"13","author":"N Zakeri","year":"2022","unstructured":"Zakeri, N. et al. Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat. Commun. 13, 1372 (2022).","journal-title":"Nat. Commun."},{"key":"1178_CR78","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1989789","volume":"10","author":"MH Nada","year":"2021","unstructured":"Nada, M. H., Wang, H., Hussein, A. J., Tanaka, Y. & Morita, C. T. PD-1 checkpoint blockade enhances adoptive immunotherapy by human V\u03b32V\u03b42 T cells against human prostate cancer. Oncoimmunology 10, 1989789 (2021).","journal-title":"Oncoimmunology"},{"key":"1178_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109871","volume":"37","author":"V Cazzetta","year":"2021","unstructured":"Cazzetta, V. et al. NKG2A expression identifies a subset of human V\u03b42 T cells exerting the highest antitumor effector functions. Cell Rep. 37, 109871 (2021).","journal-title":"Cell Rep."},{"key":"1178_CR80","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2011-01-331298","volume":"118","author":"N Caccamo","year":"2011","unstructured":"Caccamo, N. et al. Differentiation, phenotype, and function of interleukin-17-producing human V\u03b39V\u03b42 T cells. Blood 118, 129\u2013138 (2011).","journal-title":"Blood"},{"key":"1178_CR81","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.1182\/blood-2009-01-198028","volume":"113","author":"D Fenoglio","year":"2009","unstructured":"Fenoglio, D. et al. Vdelta1 T lymphocytes producing IFN-\u03b3 and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood 113, 6611\u20136618 (2009).","journal-title":"Blood"},{"key":"1178_CR82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/cmi.2015.07","volume":"13","author":"Y Mao","year":"2016","unstructured":"Mao, Y. et al. A new effect of IL-4 on human \u03b3\u03b4 T cells: promoting regulatory V\u03b41 T cells via IL-10 production and inhibiting function of V\u03b42 T cells. Cell Mol. Immunol. 13, 217\u2013228 (2016).","journal-title":"Cell Mol. Immunol."},{"key":"1178_CR83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.iotech.2019.06.002","volume":"1","author":"O Nussbaumer","year":"2019","unstructured":"Nussbaumer, O. & Koslowski, M. The emerging role of \u03b3\u03b4 T cells in cancer immunotherapy. Immunooncol. Technol. 1, 3\u201310 (2019).","journal-title":"Immunooncol. Technol."},{"key":"1178_CR84","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-083024-024653","author":"G Stevens","year":"2026","unstructured":"Stevens, G., Blanco-Dominguez, R., Mensurado, S. & Silva-Santos, B. \u03b3\u03b4 T cells for cancer immunotherapy: unconventional players take the spotlight. Annu. Rev. Immunol. https:\/\/doi.org\/10.1146\/annurev-immunol-083024-024653 (2026).","journal-title":"Annu. Rev. Immunol."},{"key":"1178_CR85","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol. Immunol. 18, 427\u2013439 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"1178_CR86","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1182\/blood.2023022992","volume":"143","author":"S Mensurado","year":"2024","unstructured":"Mensurado, S. et al. CD155\/PVR determines acute myeloid leukemia targeting by Delta One T cells. Blood 143, 1488\u20131495 (2024).","journal-title":"Blood"},{"key":"1178_CR87","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal Delta One T cells. Cancer Immunol. Res. 7, 552\u2013558 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1178_CR88","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","volume":"22","author":"AR Almeida","year":"2016","unstructured":"Almeida, A. R. et al. Delta One T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept. Clin. Cancer Res. 22, 5795\u20135804 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1178_CR89","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/jleuko\/qiae023","volume":"115","author":"M Di Simone","year":"2024","unstructured":"Di Simone, M. et al. Tumor-infiltrating \u03b3\u03b4 T cells as targets of immune checkpoint blockade in melanoma. J. Leukoc. Biol. 115, 760\u2013770 (2024).","journal-title":"J. Leukoc. Biol."},{"key":"1178_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj0835","volume":"13","author":"A De Gassart","year":"2021","unstructured":"De Gassart, A. et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell-mediated antitumor immune response. Sci. Transl. Med. 13, eabj0835 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1178_CR91","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1126\/science.aay2767","volume":"369","author":"KK Payne","year":"2020","unstructured":"Payne, K. K. et al. BTN3A1 governs antitumor responses by coordinating \u03b1\u03b2 and \u03b3\u03b4 T cells. Science 369, 942\u2013949 (2020).","journal-title":"Science"},{"key":"1178_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0715","author":"J De Bono","year":"2023","unstructured":"De Bono, J. et al. ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 study) [abstract 715]. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0715 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1178_CR93","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1158\/2326-6066.CIR-23-0868","volume":"12","author":"AC Le Floch","year":"2024","unstructured":"Le Floch, A. C. et al. Targeting BTN2A1 enhances V\u03b39V\u03b42 T-cell effector functions and triggers tumor cell pyroptosis. Cancer Immunol. Res. 12, 1677\u20131690 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"1178_CR94","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","volume":"96","author":"V Groh","year":"1999","unstructured":"Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived \u03b3\u03b4 T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96, 6879\u20136884 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1178_CR95","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284723","volume":"6","author":"M Tosolini","year":"2017","unstructured":"Tosolini, M. et al. Assessment of tumor-infiltrating TCRV\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology 6, e1284723 (2017).","journal-title":"Oncoimmunology"},{"key":"1178_CR96","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4111\/icu.2019.60.2.91","volume":"60","author":"M Vella","year":"2019","unstructured":"Vella, M. et al. Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer. Investig. Clin. Urol. 60, 91\u201398 (2019).","journal-title":"Investig. Clin. Urol."},{"key":"1178_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.517637","volume":"10","author":"Z Wu","year":"2020","unstructured":"Wu, Z. et al. The landscape of immune cells infiltrating in prostate cancer. Front. Oncol. 10, 517637 (2020).","journal-title":"Front. Oncol."},{"key":"1178_CR98","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1097\/01.ju.0000154355.45816.0b","volume":"173","author":"Z Liu","year":"2005","unstructured":"Liu, Z., Guo, B. L., Gehrs, B. C., Nan, L. & Lopez, R. D. Ex vivo expanded human V\u03b39V\u03b42+\u03b3\u03b4-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J. Urol. 173, 1552\u20131556 (2005).","journal-title":"J. Urol."},{"key":"1178_CR99","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.21873\/anticanres.14559","volume":"40","author":"M Miyashita","year":"2020","unstructured":"Miyashita, M. et al. Sphere-derived prostate cancer stem cells are resistant to \u03b3\u03b4 T cell cytotoxicity. Anticancer Res. 40, 5481\u20135487 (2020).","journal-title":"Anticancer Res."},{"key":"1178_CR100","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf0108","volume":"9","author":"JS Frieling","year":"2023","unstructured":"Frieling, J. S. et al. \u03b3\u03b4-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Sci. Adv. 9, eadf0108 (2023).","journal-title":"Sci. Adv."},{"key":"1178_CR101","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","volume":"67","author":"F Dieli","year":"2007","unstructured":"Dieli, F. et al. Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450\u20137457 (2007).","journal-title":"Cancer Res."},{"key":"1178_CR102","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3727\/096504010X12671222663638","volume":"18","author":"M Naoe","year":"2010","unstructured":"Naoe, M. et al. Zoledronate stimulates \u03b3\u03b4 T cells in prostate cancer patients. Oncol. Res. 18, 493\u2013501 (2010).","journal-title":"Oncol. Res."},{"key":"1178_CR103","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06193486 (2026)."},{"key":"1178_CR104","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05369000 (2025)."},{"key":"1178_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01653-8","volume":"8","author":"Y Hu","year":"2023","unstructured":"Hu, Y. et al. \u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy. Signal. Transduct. Target. Ther. 8, 434 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1178_CR106","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004880","volume":"10","author":"S Nguyen","year":"2022","unstructured":"Nguyen, S. et al. V\u03b42 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments. J. Immunother. Cancer 10, e004880 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1178_CR107","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41590-023-01448-7","volume":"24","author":"C Rancan","year":"2023","unstructured":"Rancan, C. et al. Exhausted intratumoral V\u03b42\u2212 \u03b3\u03b4 T cells in human kidney cancer retain effector function. Nat. Immunol. 24, 612\u2013624 (2023).","journal-title":"Nat. Immunol."},{"key":"1178_CR108","first-page":"387","volume":"10","author":"A Alexandroff","year":"1997","unstructured":"Alexandroff, A., Black, J., Bollina, P. & James, K. Differential production of gamma delta T cells in the urine of bladder cancer patients receiving Bacillus Calmette Guerin immunotherapy. Int. J. Oncol. 10, 387\u2013393 (1997).","journal-title":"Int. J. Oncol."},{"key":"1178_CR109","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.rmed.2003.12.003","volume":"98","author":"A Ponticiello","year":"2004","unstructured":"Ponticiello, A. et al. Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity. Respir. Med. 98, 509\u2013514 (2004).","journal-title":"Respir. Med."},{"key":"1178_CR110","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1128\/iai.63.12.4628-4633.1995","volume":"63","author":"P Constant","year":"1995","unstructured":"Constant, P. et al. The antituberculous Mycobacterium bovis BCG vaccine is an attenuated mycobacterial producer of phosphorylated nonpeptidic antigens for human gamma delta T cells. Infect. Immun. 63, 4628\u20134633 (1995).","journal-title":"Infect. Immun."},{"key":"1178_CR111","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.4049\/jimmunol.179.5.3057","volume":"179","author":"A Martino","year":"2007","unstructured":"Martino, A., Casetti, R., Sacchi, A. & Poccia, F. Central memory V\u03b39V\u03b42 T lymphocytes primed and expanded by bacillus Calmette-Guerin-infected dendritic cells kill mycobacterial-infected monocytes. J. Immunol. 179, 3057\u20133064 (2007).","journal-title":"J. Immunol."},{"key":"1178_CR112","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1158\/2326-6066.CIR-21-0285","volume":"9","author":"N Ji","year":"2021","unstructured":"Ji, N. et al. \u03b3\u03b4 T cells support antigen-specific \u03b1\u03b2 T cell-mediated antitumor responses during BCG treatment for bladder cancer. Cancer Immunol. Res. 9, 1491\u20131503 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"1178_CR113","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","volume":"15","author":"MS Zaghloul","year":"2010","unstructured":"Zaghloul, M. S. et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int. J. Clin. Oncol. 15, 382\u2013389 (2010).","journal-title":"Int. J. Clin. Oncol."},{"key":"1178_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001941","volume":"9","author":"N Ji","year":"2021","unstructured":"Ji, N. et al. Rapamycin enhances BCG-specific \u03b3\u03b4 T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J. Immunother. Cancer 9, e001941 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1178_CR115","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04375813 (2026)."},{"key":"1178_CR116","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cmet.2020.01.015","volume":"31","author":"A Gonzalez","year":"2020","unstructured":"Gonzalez, A., Hall, M. N., Lin, S. C. & Hardie, D. G. AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control. Cell Metab. 31, 472\u2013492 (2020).","journal-title":"Cell Metab."},{"key":"1178_CR117","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.4049\/jimmunol.154.8.3932","volume":"154","author":"A Choudhary","year":"1995","unstructured":"Choudhary, A. et al. Selective lysis of autologous tumor cells by recurrent \u03b3\u03b4 tumor-infiltrating lymphocytes from renal carcinoma. J. Immunol. 154, 3932\u20133940 (1995).","journal-title":"J. Immunol."},{"key":"1178_CR118","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1046\/j.1464-410X.1997.00408.x","volume":"80","author":"D Kowalczyk","year":"1997","unstructured":"Kowalczyk, D., Skorupski, W., Kwias, Z. & Nowak, J. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br. J. Urol. 80, 543\u2013547 (1997).","journal-title":"Br. J. Urol."},{"key":"1178_CR119","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.4049\/jimmunol.180.5.3578","volume":"180","author":"BA Inman","year":"2008","unstructured":"Inman, B. A. et al. Questionable relevance of \u03b3\u03b4 T lymphocytes in renal cell carcinoma. J. Immunol. 180, 3578\u20133584 (2008).","journal-title":"J. Immunol."},{"key":"1178_CR120","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.4049\/jimmunol.174.3.1338","volume":"174","author":"E Viey","year":"2005","unstructured":"Viey, E. et al. Phosphostim-activated \u03b3\u03b4 T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174, 1338\u20131347 (2005).","journal-title":"J. Immunol."},{"key":"1178_CR121","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CJI.0b013e3181609988","volume":"31","author":"E Viey","year":"2008","unstructured":"Viey, E. et al. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded V\u03b39V\u03b42 T cells from renal cell carcinoma patients. J. Immunother. 31, 313\u2013323 (2008).","journal-title":"J. Immunother."},{"key":"1178_CR122","first-page":"1027","volume":"31","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi, H. et al. A new indicator of favorable prognosis in locally advanced renal cell carcinomas: \u03b3\u03b4 T-cells in peripheral blood. Anticancer Res. 31, 1027\u20131031 (2011).","journal-title":"Anticancer Res."},{"key":"1178_CR123","doi-asserted-by":"publisher","first-page":"488.e1","DOI":"10.1016\/j.urolonc.2023.10.001","volume":"41","author":"H Kobayashi","year":"2023","unstructured":"Kobayashi, H., Kondo, T., Iizuka, J., Yoshida, K. & Takagi, T. A retrospective cohort study of the impact of peripheral blood gamma- delta T cells to prognosis of nonmetastatic renal cell cancer after curative resection. Urol. Oncol. 41, 488.e1\u2013488.e9 (2023).","journal-title":"Urol. Oncol."},{"key":"1178_CR124","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","volume":"57","author":"J Bennouna","year":"2008","unstructured":"Bennouna, J. et al. Phase-I study of Innacell \u03b3\u03b4, an autologous cell-therapy product highly enriched in \u03b39\u03b42 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57, 1599\u20131609 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"1178_CR125","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00262-010-0879-0","volume":"59","author":"J Bennouna","year":"2010","unstructured":"Bennouna, J. et al. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V\u03b39V\u03b42 T lymphocyte agonist in patients with solid tumors. Cancer Immunol. Immunother. 59, 1521\u20131530 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"1178_CR126","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","volume":"56","author":"H Kobayashi","year":"2007","unstructured":"Kobayashi, H. et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56, 469\u2013476 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"1178_CR127","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","volume":"35","author":"V Kunzmann","year":"2012","unstructured":"Kunzmann, V. et al. Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4 T cells in cancer immunotherapy: results from a prospective phase I\/II trial. J. Immunother. 35, 205\u2013213 (2012).","journal-title":"J. Immunother."},{"key":"1178_CR128","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","volume":"60","author":"JM Lang","year":"2011","unstructured":"Lang, J. M. et al. Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4 T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol. Immunother. 60, 1447\u20131460 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"1178_CR129","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","volume":"60","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N. & Tanabe, K. Phase I\/II study of adoptive transfer of \u03b3\u03b4 T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol. Immunother. 60, 1075\u20131084 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"1178_CR130","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06480565 (2025)."},{"key":"1178_CR131","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231487","volume":"221","author":"H Bugaut","year":"2024","unstructured":"Bugaut, H. et al. A conserved transcriptional program for MAIT cells across mammalian evolution. J. Exp. Med. 221, e20231487 (2024).","journal-title":"J. Exp. Med."},{"key":"1178_CR132","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nature01433","volume":"422","author":"E Treiner","year":"2003","unstructured":"Treiner, E. et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422, 164\u2013169 (2003).","journal-title":"Nature"},{"key":"1178_CR133","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","volume":"20","author":"DI Godfrey","year":"2019","unstructured":"Godfrey, D. I., Koay, H. F., McCluskey, J. & Gherardin, N. A. The biology and functional importance of MAIT cells. Nat. Immunol. 20, 1110\u20131128 (2019).","journal-title":"Nat. Immunol."},{"key":"1178_CR134","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/ni.3565","volume":"17","author":"HF Koay","year":"2016","unstructured":"Koay, H. F. et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat. Immunol. 17, 1300\u20131311 (2016).","journal-title":"Nat. Immunol."},{"key":"1178_CR135","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay6039","volume":"4","author":"HF Koay","year":"2019","unstructured":"Koay, H. F. et al. A divergent transcriptional landscape underpins the development and functional branching of MAIT cells. Sci. Immunol. 4, eaay6039 (2019).","journal-title":"Sci. Immunol."},{"key":"1178_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22130-1","volume":"8","author":"NA Gherardin","year":"2018","unstructured":"Gherardin, N. A. et al. Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Sci. Rep. 8, 4159 (2018).","journal-title":"Sci. Rep."},{"key":"1178_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1367","volume":"11","author":"VM Vorwald","year":"2022","unstructured":"Vorwald, V. M. et al. Circulating CD8+ mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients. Clin. Transl. Immunol. 11, e1367 (2022).","journal-title":"Clin. Transl. Immunol."},{"key":"1178_CR138","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","volume":"117","author":"M Dusseaux","year":"2011","unstructured":"Dusseaux, M. et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117, 1250\u20131259 (2011).","journal-title":"Blood"},{"key":"1178_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01014","volume":"11","author":"TSC Hinks","year":"2020","unstructured":"Hinks, T. S. C. & Zhang, X. W. MAIT cell activation and functions. Front. Immunol. 11, 1014 (2020).","journal-title":"Front. Immunol."},{"key":"1178_CR140","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1016\/j.celrep.2019.08.054","volume":"28","author":"R Lamichhane","year":"2019","unstructured":"Lamichhane, R. et al. TCR- or cytokine-activated CD8+ mucosal-associated invariant T cells are rapid polyfunctional effectors that can coordinate immune responses. Cell Rep. 28, 3061\u20133076.e5 (2019).","journal-title":"Cell Rep."},{"key":"1178_CR141","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature11605","volume":"491","author":"L Kjer-Nielsen","year":"2012","unstructured":"Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717\u2013723 (2012).","journal-title":"Nature"},{"key":"1178_CR142","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature13160","volume":"509","author":"AJ Corbett","year":"2014","unstructured":"Corbett, A. J. et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 509, 361\u2013365 (2014).","journal-title":"Nature"},{"key":"1178_CR143","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.tig.2003.11.008","volume":"20","author":"AG Vitreschak","year":"2004","unstructured":"Vitreschak, A. G., Rodionov, D. A., Mironov, A. A. & Gelfand, M. S. Riboswitches: the oldest mechanism for the regulation of gene expression? Trends Genet. 20, 44\u201350 (2004).","journal-title":"Trends Genet."},{"key":"1178_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005902","volume":"11","author":"L Shi","year":"2023","unstructured":"Shi, L. et al. Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy. J. Immunother. Cancer 11, e005902 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1178_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25009-4","volume":"12","author":"EV Petley","year":"2021","unstructured":"Petley, E. V. et al. MAIT cells regulate NK cell-mediated tumor immunity. Nat. Commun. 12, 4746 (2021).","journal-title":"Nat. Commun."},{"key":"1178_CR146","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2159-8290.CD-19-0569","volume":"10","author":"J Yan","year":"2020","unstructured":"Yan, J. et al. MAIT cells promote tumor initiation, growth, and metastases via tumor MR1. Cancer Discov. 10, 124\u2013141 (2020).","journal-title":"Cancer Discov."},{"key":"1178_CR147","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2326-6066.CIR-20-0925","volume":"9","author":"B Ruf","year":"2021","unstructured":"Ruf, B. et al. Activating mucosal-associated invariant T cells induces a broad antitumor response. Cancer Immunol. Res. 9, 1024\u20131034 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"1178_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.748741","volume":"12","author":"EM Jarvis","year":"2021","unstructured":"Jarvis, E. M. et al. Mucosal-associated invariant T (MAIT) cell dysfunction and PD-1 expression in prostate cancer: implications for immunotherapy. Front. Immunol. 12, 748741 (2021).","journal-title":"Front. Immunol."},{"key":"1178_CR149","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1007\/s00262-021-02939-y","volume":"70","author":"W Rodin","year":"2021","unstructured":"Rodin, W. et al. Exhaustion in tumor-infiltrating mucosal-associated invariant T (MAIT) cells from colon cancer patients. Cancer Immunol. Immunother. 70, 3461\u20133475 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"1178_CR150","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","volume":"186","author":"B Ruf","year":"2023","unstructured":"Ruf, B. et al. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Cell 186, 3686\u20133705.e32 (2023).","journal-title":"Cell"},{"key":"1178_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21928-4","volume":"12","author":"S De Biasi","year":"2021","unstructured":"De Biasi, S. et al. Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy. Nat. Commun. 12, 1669 (2021).","journal-title":"Nat. Commun."},{"key":"1178_CR152","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.4049\/jimmunol.2100856","volume":"209","author":"M Dogan","year":"2022","unstructured":"Dogan, M. et al. Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy. J. Immunol. 209, 1523\u20131531 (2022).","journal-title":"J. Immunol."},{"key":"1178_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4866","volume":"5","author":"M Lepore","year":"2014","unstructured":"Lepore, M. et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCR\u03b2 repertoire. Nat. Commun. 5, 3866 (2014).","journal-title":"Nat. Commun."},{"key":"1178_CR154","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1172\/JCI82424","volume":"125","author":"Y Cui","year":"2015","unstructured":"Cui, Y. et al. Mucosal-associated invariant T cell-rich congenic mouse strain allows functional evaluation. J. Clin. Invest. 125, 4171\u20134185 (2015).","journal-title":"J. Clin. Invest."},{"key":"1178_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111892","volume":"133","author":"B Zhang","year":"2024","unstructured":"Zhang, B., Chen, P., Zhu, J. & Lu, Y. The quantity, function and anti-tumor effect of mucosal associated invariant T cells in patients with bladder cancer. Int. Immunopharmacol. 133, 111892 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"1178_CR156","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012496","volume":"13","author":"IA Habaz","year":"2025","unstructured":"Habaz, I. A. et al. MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment. J. Immunother. Cancer 13, e012496 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1178_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01136","volume":"11","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Mucosal-associated invariant T cells develop an innate-like transcriptomic program in anti-mycobacterial responses. Front. Immunol. 11, 1136 (2020).","journal-title":"Front. Immunol."},{"key":"1178_CR158","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.4049\/jimmunol.1900674","volume":"203","author":"S Suliman","year":"2019","unstructured":"Suliman, S. et al. MR1-independent activation of human mucosal-associated invariant T cells by mycobacteria. J. Immunol. 203, 2917\u20132927 (2019).","journal-title":"J. Immunol."},{"key":"1178_CR159","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03865-21","volume":"13","author":"RJ Dey","year":"2021","unstructured":"Dey, R. J. et al. Augmentation of the riboflavin-biosynthetic pathway enhances mucosa-associated invariant T (MAIT) cell activation and diminishes mycobacterium tuberculosis virulence. mBio 13, e0386521 (2021).","journal-title":"mBio"},{"key":"1178_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43269-0","volume":"14","author":"AC Gnirck","year":"2023","unstructured":"Gnirck, A. C. et al. Mucosal-associated invariant T cells contribute to suppression of inflammatory myeloid cells in immune-mediated kidney disease. Nat. Commun. 14, 7372 (2023).","journal-title":"Nat. Commun."},{"key":"1178_CR161","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/eji.202048644","volume":"50","author":"ML Terpstra","year":"2020","unstructured":"Terpstra, M. L. et al. Tissue-resident mucosal-associated invariant T (MAIT) cells in the human kidney represent a functionally distinct subset. Eur. J. Immunol. 50, 1783\u20131797 (2020).","journal-title":"Eur. J. Immunol."},{"key":"1178_CR162","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/intimm\/dxn111","volume":"20","author":"A Peterfalvi","year":"2008","unstructured":"Peterfalvi, A. et al. Invariant V\u03b17.2-J\u03b133 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells. Int. Immunol. 20, 1517\u20131525 (2008).","journal-title":"Int. Immunol."},{"key":"1178_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100039","volume":"1","author":"S Li","year":"2020","unstructured":"Li, S. et al. Human tumor-infiltrating MAIT cells display hallmarks of bacterial antigen recognition in colorectal cancer. Cell Rep. Med. 1, 100039 (2020).","journal-title":"Cell Rep. Med."},{"key":"1178_CR164","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04163289 (2025)."},{"key":"1178_CR165","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00262-022-03329-8","volume":"72","author":"M Ninkov","year":"2023","unstructured":"Ninkov, M. et al. Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma. Cancer Immunol. Immunother. 72, 1247\u20131260 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"1178_CR166","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.4049\/jimmunol.164.5.2412","volume":"164","author":"MC Coles","year":"2000","unstructured":"Coles, M. C. & Raulet, D. H. NK1.1+ T cells in the liver arise in the thymus and are selected by interactions with class I molecules on CD4+CD8+ cells. J. Immunol. 164, 2412\u20132418 (2000).","journal-title":"J. Immunol."},{"key":"1178_CR167","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nri2116","volume":"7","author":"DI Godfrey","year":"2007","unstructured":"Godfrey, D. I. & Berzins, S. P. Control points in NKT-cell development. Nat. Rev. Immunol. 7, 505\u2013518 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"1178_CR168","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"A Bendelac","year":"2007","unstructured":"Bendelac, A., Savage, P. B. & Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297\u2013336 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"1178_CR169","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri1309","volume":"4","author":"DI Godfrey","year":"2004","unstructured":"Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. & Van Kaer, L. NKT cells: what\u2019s in a name? Nat. Rev. Immunol. 4, 231\u2013237 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"1178_CR170","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","volume":"278","author":"T Kawano","year":"1997","unstructured":"Kawano, T. et al. CD1d-restricted and TCR-mediated activation of V\u03b114 NKT cells by glycosylceramides. Science 278, 1626\u20131629 (1997).","journal-title":"Science"},{"key":"1178_CR171","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-8-116","volume":"8","author":"BR Dias","year":"2009","unstructured":"Dias, B. R. et al. Identification of iGb3 and iGb4 in melanoma B16F10-Nex2 cells and the iNKT cell-mediated antitumor effect of dendritic cells primed with iGb3. Mol. Cancer 8, 116 (2009).","journal-title":"Mol. Cancer"},{"key":"1178_CR172","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060181","volume":"6","author":"C Sedwick","year":"2008","unstructured":"Sedwick, C. Starting over: the search for endogenous NKT cell ligands. PLoS Biol. 6, e181 (2008).","journal-title":"PLoS Biol."},{"key":"1178_CR173","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.4049\/jimmunol.1601399","volume":"198","author":"MV Dhodapkar","year":"2017","unstructured":"Dhodapkar, M. V. & Kumar, V. Type II NKT cells and their emerging role in health and disease. J. Immunol. 198, 1015\u20131021 (2017).","journal-title":"J. Immunol."},{"key":"1178_CR174","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nri3369","volume":"13","author":"PJ Brennan","year":"2013","unstructured":"Brennan, P. J., Brigl, M. & Brenner, M. B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13, 101\u2013117 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1178_CR175","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1084\/jem.20011786","volume":"195","author":"JE Gumperz","year":"2002","unstructured":"Gumperz, J. E., Miyake, S., Yamamura, T. & Brenner, M. B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195, 625\u2013636 (2002).","journal-title":"J. Exp. Med."},{"key":"1178_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108116","volume":"32","author":"T Baranek","year":"2020","unstructured":"Baranek, T. et al. High dimensional single-cell analysis reveals iNKT cell developmental trajectories and effector fate decision. Cell Rep. 32, 108116 (2020).","journal-title":"Cell Rep."},{"key":"1178_CR177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00570","volume":"8","author":"CW Keller","year":"2017","unstructured":"Keller, C. W., Freigang, S. & Lunemann, J. D. Reciprocal crosstalk between dendritic cells and natural killer T cells: mechanisms and therapeutic potential. Front. Immunol. 8, 570 (2017).","journal-title":"Front. Immunol."},{"key":"1178_CR178","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.4049\/jimmunol.1300033","volume":"190","author":"K Shimizu","year":"2013","unstructured":"Shimizu, K. et al. Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J. Immunol. 190, 5609\u20135619 (2013).","journal-title":"J. Immunol."},{"key":"1178_CR179","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.4049\/jimmunol.170.5.2540","volume":"170","author":"D Stober","year":"2003","unstructured":"Stober, D., Jomantaite, I., Schirmbeck, R. & Reimann, J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J. Immunol. 170, 2540\u20132548 (2003).","journal-title":"J. Immunol."},{"key":"1178_CR180","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4049\/jimmunol.182.1.250","volume":"182","author":"T Kawamura","year":"2009","unstructured":"Kawamura, T. et al. NKG2A inhibits invariant NKT cell activation in hepatic injury. J. Immunol. 182, 250\u2013258 (2009).","journal-title":"J. Immunol."},{"key":"1178_CR181","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/eji.200940278","volume":"41","author":"C Kuylenstierna","year":"2011","unstructured":"Kuylenstierna, C. et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur. J. Immunol. 41, 1913\u20131923 (2011).","journal-title":"Eur. J. Immunol."},{"key":"1178_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36468-8","volume":"13","author":"AL Balasko","year":"2023","unstructured":"Balasko, A. L., Kowatsch, M. M., Graydon, C., Lajoie, J. & Fowke, K. R. The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant natural killer T cell function. Sci. Rep. 13, 10082 (2023).","journal-title":"Sci. Rep."},{"key":"1178_CR183","first-page":"529","volume":"7","author":"E Kobayashi","year":"1995","unstructured":"Kobayashi, E., Motoki, K., Uchida, T., Fukushima, H. & Koezuka, Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7, 529\u2013534 (1995).","journal-title":"Oncol. Res."},{"key":"1178_CR184","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-05-0877","volume":"11","author":"T Tachibana","year":"2005","unstructured":"Tachibana, T. et al. Increased intratumor V\u03b124-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11, 7322\u20137327 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1178_CR185","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/blood-2016-11-751065","volume":"129","author":"F Gorini","year":"2017","unstructured":"Gorini, F. et al. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood 129, 3440\u20133451 (2017).","journal-title":"Blood"},{"key":"1178_CR186","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1200\/JCO.2006.08.5787","volume":"25","author":"JW Molling","year":"2007","unstructured":"Molling, J. W. et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 25, 862\u2013868 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1178_CR187","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.4049\/jimmunol.179.8.5126","volume":"179","author":"E Ambrosino","year":"2007","unstructured":"Ambrosino, E. et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J. Immunol. 179, 5126\u20135136 (2007).","journal-title":"J. Immunol."},{"key":"1178_CR188","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey, A. et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat. Med. 29, 1379\u20131388 (2023).","journal-title":"Nat. Med."},{"key":"1178_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56270-6","volume":"16","author":"YR Li","year":"2025","unstructured":"Li, Y. R. et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat. Commun. 16, 1248 (2025).","journal-title":"Nat. Commun."},{"key":"1178_CR190","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","volume":"167","author":"SM Tahir","year":"2001","unstructured":"Tahir, S. M. et al. Loss of IFN-\u03b3 production by invariant NK T cells in advanced cancer. J. Immunol. 167, 4046\u20134050 (2001).","journal-title":"J. Immunol."},{"key":"1178_CR191","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011311","volume":"5","author":"M Nowak","year":"2010","unstructured":"Nowak, M. et al. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. PLoS ONE 5, e11311 (2010).","journal-title":"PLoS ONE"},{"key":"1178_CR192","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.celrep.2018.02.058","volume":"22","author":"F Cortesi","year":"2018","unstructured":"Cortesi, F. et al. Bimodal CD40\/Fas-dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression. Cell Rep. 22, 3006\u20133020 (2018).","journal-title":"Cell Rep."},{"key":"1178_CR193","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1016\/j.cell.2023.05.028","volume":"186","author":"H Guo","year":"2023","unstructured":"Guo, H. et al. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell 186, 2765\u20132782.e28 (2023).","journal-title":"Cell"},{"key":"1178_CR194","first-page":"121","volume":"21","author":"A Ariafar","year":"2024","unstructured":"Ariafar, A., Kohansal, E., Mousania, A. & Faghih, Z. Natural killer cell subsets in tumor draining lymph nodes of patients with bladder cancer and their clinical implications. Iran. J. Immunol. 21, 121\u2013131 (2024).","journal-title":"Iran. J. Immunol."},{"key":"1178_CR195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","volume":"11","author":"CJ Lim","year":"2020","unstructured":"Lim, C. J. et al. Immunological hallmarks for clinical response to BCG in bladder cancer. Front. Immunol. 11, 615091 (2020).","journal-title":"Front. Immunol."},{"key":"1178_CR196","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","volume":"66","author":"CA Rentsch","year":"2014","unstructured":"Rentsch, C. A. et al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur. Urol. 66, 677\u2013688 (2014).","journal-title":"Eur. Urol."},{"key":"1178_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33253-w","volume":"8","author":"E Noguera-Ortega","year":"2018","unstructured":"Noguera-Ortega, E. et al. Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice. Sci. Rep. 8, 15102 (2018).","journal-title":"Sci. Rep."},{"key":"1178_CR198","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1778-6","volume":"17","author":"H Furuya","year":"2019","unstructured":"Furuya, H. et al. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. J. Transl. Med. 17, 29 (2019).","journal-title":"J. Transl. Med."},{"key":"1178_CR199","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","volume":"14","author":"M Naoe","year":"2007","unstructured":"Naoe, M. et al. Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and \u03b3\u03b4T cells. Int. J. Urol. 14, 532\u2013538 (2007).","journal-title":"Int. J. Urol."},{"key":"1178_CR200","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/(SICI)1521-4141(199902)29:02<650::AID-IMMU650>3.0.CO;2-M","volume":"29","author":"M Emoto","year":"1999","unstructured":"Emoto, M., Emoto, Y., Buchwalow, I. B. & Kaufmann, S. H. Induction of IFN-\u03b3-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guerin. Eur. J. Immunol. 29, 650\u2013659 (1999).","journal-title":"Eur. J. Immunol."},{"key":"1178_CR201","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1097\/01.ju.0000158122.16046.68","volume":"173","author":"S Minagawa","year":"2005","unstructured":"Minagawa, S. et al. Activation of natural killer T cells by \u03b1-galactosylceramide mediates clearance of bacteria in murine urinary tract infection. J. Urol. 173, 2171\u20132174 (2005).","journal-title":"J. Urol."},{"key":"1178_CR202","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2249.2010.04274.x","volume":"162","author":"FA Vyth-Dreese","year":"2010","unstructured":"Vyth-Dreese, F. A. et al. Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma. Clin. Exp. Immunol. 162, 447\u2013459 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"1178_CR203","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.985082","volume":"4","author":"K Geissler","year":"2015","unstructured":"Geissler, K. et al. Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology 4, e985082 (2015).","journal-title":"Oncoimmunology"},{"key":"1178_CR204","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1158\/0008-5472.CAN-06-0250","volume":"66","author":"K Biswas","year":"2006","unstructured":"Biswas, K. et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res. 66, 6816\u20136825 (2006).","journal-title":"Cancer Res."},{"key":"1178_CR205","doi-asserted-by":"publisher","first-page":"6642","DOI":"10.4049\/jimmunol.178.10.6642","volume":"178","author":"G Raval","year":"2007","unstructured":"Raval, G. et al. TNF \u03b1 induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction. J. Immunol. 178, 6642\u20136652 (2007).","journal-title":"J. Immunol."},{"key":"1178_CR206","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1136\/jclinpath-2014-202735","volume":"68","author":"TW Chong","year":"2015","unstructured":"Chong, T. W. et al. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival. J. Clin. Pathol. 68, 200\u2013205 (2015).","journal-title":"J. Clin. Pathol."},{"key":"1178_CR207","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.4049\/jimmunol.0802964","volume":"182","author":"MW Teng","year":"2009","unstructured":"Teng, M. W., Yue, S., Sharkey, J., Exley, M. A. & Smyth, M. J. CD1d activation and blockade: a new antitumor strategy. J. Immunol. 182, 3366\u20133371 (2009).","journal-title":"J. Immunol."},{"key":"1178_CR208","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.4049\/jimmunol.0900796","volume":"183","author":"MW Teng","year":"2009","unstructured":"Teng, M. W., Sharkey, J., McLaughlin, N. M., Exley, M. A. & Smyth, M. J. CD1d-based combination therapy eradicates established tumors in mice. J. Immunol. 183, 1911\u20131920 (2009).","journal-title":"J. Immunol."},{"key":"1178_CR209","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06870279 (2025)."},{"key":"1178_CR210","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06182735 (2023)."},{"key":"1178_CR211","first-page":"S881","volume":"32","author":"J Zhang","year":"2024","unstructured":"Zhang, J. Interim safety and efficacy of anti-CD70 CAR-NKT (CGC729) for patients with advanced renal cell carcinoma [abstract 1896]. Mol. Ther. 32, S881\u2013S882 (2024).","journal-title":"Mol. Ther."},{"key":"1178_CR212","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103757","volume":"24","author":"MR Alam","year":"2025","unstructured":"Alam, M. R. et al. CD4(+)CD8(+) double-positive T cells in immune disorders and cancer: prospects and hurdles in immunotherapy. Autoimmun. Rev. 24, 103757 (2025).","journal-title":"Autoimmun. Rev."},{"key":"1178_CR213","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/imm.13441","volume":"165","author":"T Velikkakam","year":"2022","unstructured":"Velikkakam, T., Gollob, K. J. & Dutra, W. O. Double-negative T cells: setting the stage for disease control or progression. Immunology 165, 371\u2013385 (2022).","journal-title":"Immunology"},{"key":"1178_CR214","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/JLB.1AB0120-548R","volume":"108","author":"N Rodriguez-Rodriguez","year":"2020","unstructured":"Rodriguez-Rodriguez, N. et al. TCR-\u03b1\/\u03b2 CD4\u2212 CD8\u2212 double negative T cells arise from CD8+ T cells. J. Leukoc. Biol. 108, 851\u2013857 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"1178_CR215","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212169","volume":"219","author":"SE Schad","year":"2022","unstructured":"Schad, S. E. et al. Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. J. Exp. Med. 219, e20212169 (2022).","journal-title":"J. Exp. Med."},{"key":"1178_CR216","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood.V91.11.4331","volume":"91","author":"M Bagot","year":"1998","unstructured":"Bagot, M. et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 91, 4331\u20134341 (1998).","journal-title":"Blood"},{"key":"1178_CR217","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008437","volume":"5","author":"J Desfrancois","year":"2010","unstructured":"Desfrancois, J. et al. Double positive CD4CD8 \u03b1\u03b2 T cells: a new tumor-reactive population in human melanomas. PLoS ONE 5, e8437 (2010).","journal-title":"PLoS ONE"},{"key":"1178_CR218","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/eji.200636991","volume":"37","author":"MS Ford","year":"2007","unstructured":"Ford, M. S. et al. Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. Eur. J. Immunol. 37, 2234\u20132241 (2007).","journal-title":"Eur. J. Immunol."},{"key":"1178_CR219","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004396","volume":"10","author":"Z Mou","year":"2014","unstructured":"Mou, Z. et al. MHC class II restricted innate-like double negative T cells contribute to optimal primary and secondary immunity to Leishmania major. PLoS Pathog. 10, e1004396 (2014).","journal-title":"PLoS Pathog."},{"key":"1178_CR220","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00622","volume":"10","author":"P Bohner","year":"2019","unstructured":"Bohner, P. et al. Double positive CD4+CD8+ T Cells are enriched in urological cancers and favor T helper-2 polarization. Front. Immunol. 10, 622 (2019).","journal-title":"Front. Immunol."},{"key":"1178_CR221","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/intimm\/dxaa004","volume":"32","author":"K Nishida","year":"2020","unstructured":"Nishida, K. et al. Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. Int. Immunol. 32, 347\u2013357 (2020).","journal-title":"Int. Immunol."},{"key":"1178_CR222","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02728","volume":"9","author":"LC Menard","year":"2018","unstructured":"Menard, L. C. et al. Renal cell carcinoma (RCC) tumors display large expansion of double positive (DP) CD4+CD8+ T cells with expression of exhaustion markers. Front. Immunol. 9, 2728 (2018).","journal-title":"Front. Immunol."},{"key":"1178_CR223","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.952252","volume":"12","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes. Front. Oncol. 12, 952252 (2022).","journal-title":"Front. Oncol."},{"key":"1178_CR224","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1681\/ASN.2014121214","volume":"27","author":"MN Martina","year":"2016","unstructured":"Martina, M. N. et al. Double-negative \u03b1\u03b2 T cells are early responders to AKI and are found in human kidney. J. Am. Soc. Nephrol. 27, 1113\u20131123 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1178_CR225","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460275","volume":"15","author":"H Un","year":"2024","unstructured":"Un, H. et al. Understanding bladder cancer risk: Mendelian randomization analysis of immune cell and inflammatory factor influence. Front. Immunol. 15, 1460275 (2024).","journal-title":"Front. Immunol."},{"key":"1178_CR226","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1021\/ja309557s","volume":"135","author":"K Janthawornpong","year":"2013","unstructured":"Janthawornpong, K. et al. Inhibition of IspH, a [4Fe-4S]2+ enzyme involved in the biosynthesis of isoprenoids via the methylerythritol phosphate pathway. J. Am. Chem. Soc. 135, 1816\u20131822 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"1178_CR227","doi-asserted-by":"publisher","DOI":"10.5802\/crchim.254","author":"BE Petit","year":"2023","unstructured":"Petit, B. E. Synthesis and kinetic evaluation of analogs of (E)-4-amino-3-methylbut-2-en-1-yl diphosphate, a potent inhibitor of the IspH metalloenzyme. C. R. Chim. https:\/\/doi.org\/10.5802\/crchim.254 (2023).","journal-title":"C. R. Chim."},{"key":"1178_CR228","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01664-8","volume":"18","author":"Z Li","year":"2025","unstructured":"Li, Z., Wrangle, J., He, K., Sprent, J. & Rubinstein, M. P. IL-15: from discovery to FDA approval. J. Hematol. Oncol. 18, 19 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1178_CR229","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.omto.2021.11.006","volume":"23","author":"JL Green","year":"2021","unstructured":"Green, J. L. et al. Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance. Mol. Ther. Oncolytics 23, 547\u2013559 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1178_CR230","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.eururo.2025.12.022","volume":"89","author":"P Scilipoti","year":"2026","unstructured":"Scilipoti, P. et al. Efficacy and safety of checkpoint inhibitors combined with Bacillus Calmette-Guerin (BCG) in BCG-naive high-risk non-muscle-invasive bladder cancer: synthesis of evidence from the ALBAN, CREST, and POTOMAC trials. Eur. Urol. 89, 204\u2013209 (2026).","journal-title":"Eur. Urol."},{"key":"1178_CR231","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/JLB.5MA1219-296R","volume":"107","author":"N Beucke","year":"2020","unstructured":"Beucke, N. et al. Pitfalls in the characterization of circulating and tissue-resident human \u03b3\u03b4 T cells. J. Leukoc. Biol. 107, 1097\u20131105 (2020).","journal-title":"J. Leukoc. Biol"},{"key":"1178_CR232","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/cyto.a.22470","volume":"A 85","author":"K Wistuba\u2010Hamprecht","year":"2014","unstructured":"Wistuba\u2010Hamprecht, K., Pawelec, G. & Derhovanessian, E. OMIP\u2010020: phenotypic characterization of human \u03b3\u03b4 T\u2010cells by multicolor flow cytometry. Cytom. A 85, 522\u2013524 (2014).","journal-title":"Cytom. A"},{"key":"1178_CR233","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/cyto.a.24272","volume":"99","author":"SR Wang","year":"2021","unstructured":"Wang, S.-R. et al. OMIP 071: a 31\u2010parameter flow cytometry panel for in\u2010depth immunophenotyping of human T\u2010cell subsets using surface markers. Cytom. A 99, 273\u2013277 (2021).","journal-title":"Cytom. A"},{"key":"1178_CR234","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/cyto.a.24529","volume":"101","author":"CM Doyle","year":"2022","unstructured":"Doyle, C. M. et al. OMIP 082: a 25\u2010color phenotyping to define human innate lymphoid cells natural killer cells mucosal\u2010associated invariant T cells and \u03b3\u03b4 T cells from freshly isolated human intestinal tissue. Cytom. A 101, 196\u2013202 (2022).","journal-title":"Cytom. A"},{"key":"1178_CR235","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/cyto.a.24738","volume":"103","author":"J Anderson","year":"2023","unstructured":"Anderson, J., Jalali, S., Licciardi, P. V. & Pellicci, D. G. OMIP\u201091: a 27\u2010color flow cytometry panel to evaluate the phenotype and function of human conventional and unconventional T\u2010cells. Cytom. A 103, 543\u2013547 (2023).","journal-title":"Cytom. A"},{"key":"1178_CR236","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/cyto.a.24841","volume":"105","author":"AJ Konecny","year":"2024","unstructured":"Konecny, A. J., Mage, P. L., Tyznik, A. J., Prlic, M. & Mair, F. OMIP\u2010102: 50\u2010color phenotyping of the human immune system with in\u2010depth assessment of T cells and dendritic cells. Cytom. A 105, 430\u2013436 (2024).","journal-title":"Cytom. A"},{"key":"1178_CR237","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cyto.a.24914","volume":"107","author":"Q Jiang","year":"2025","unstructured":"Jiang, Q. et al. OMIP\u2010110: a 37\u2010color spectral flow cytometric panel to assess transcription factors and chemokine receptors in human intestinal lymphoid cells. Cytom. A 107, 9\u201335 (2025).","journal-title":"Cytom. A"},{"key":"1178_CR238","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/cyto.a.22326","volume":"83","author":"YD Mahnke","year":"2013","unstructured":"Mahnke, Y. D., Beddall, M. H. & Roederer, M. OMIP\u2010019: quantification of human \u03b3\u03b4T\u2010cells iNKT\u2010cells and hematopoietic precursors. Cytom. A 83, 676\u2013678 (2013).","journal-title":"Cytom. A"},{"key":"1178_CR239","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/cyto.a.22475","volume":"85","author":"NA Gherardin","year":"2014","unstructured":"Gherardin, N. A., Ritchie, D. S., Godfrey, D. I. & Neeson, P. J. OMIP\u2010021: simultaneous quantification of human conventional and innate\u2010like T\u2010cell subsets. Cytom. A 85, 573\u2013575 (2014).","journal-title":"Cytom. A"},{"key":"1178_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10198-w","volume":"10","author":"HF Koay","year":"2019","unstructured":"Koay, H. F. et al. Diverse MR1-restricted T cells in mice and humans. Nat. Commun. 10, 2243 (2019).","journal-title":"Nat. Commun."},{"key":"1178_CR241","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41590-019-0578-8","volume":"21","author":"MD Crowther","year":"2020","unstructured":"Crowther, M. D. et al. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat. Immunol. 21, 178\u2013185 (2020).","journal-title":"Nat. Immunol."},{"key":"1178_CR242","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12506","volume":"7","author":"EW Meermeier","year":"2016","unstructured":"Meermeier, E. W. et al. Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens. Nat. Commun. 7, 12506 (2016).","journal-title":"Nat. Commun."},{"key":"1178_CR243","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.molimm.2020.12.009","volume":"130","author":"M Lepore","year":"2021","unstructured":"Lepore, M., Lewinsohn, D. A. & Lewinsohn, D. M. T cell receptor diversity, specificity and promiscuity of functionally heterogeneous human MR1-restricted T cells. Mol. Immunol. 130, 64\u201368 (2021).","journal-title":"Mol. Immunol."},{"key":"1178_CR244","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/imr.12322","volume":"267","author":"A de Jong","year":"2015","unstructured":"de Jong, A. Activation of human T cells by CD1 and self-lipids. Immunol. Rev. 267, 16\u201329 (2015).","journal-title":"Immunol. Rev."},{"key":"1178_CR245","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/ni.2630","volume":"14","author":"I Van Rhijn","year":"2013","unstructured":"Van Rhijn, I. et al. A conserved human T cell population targets mycobacterial antigens presented by CD1b. Nat. Immunol. 14, 706\u2013713 (2013).","journal-title":"Nat. Immunol."},{"key":"1178_CR246","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13257","volume":"7","author":"S Gras","year":"2016","unstructured":"Gras, S. et al. T cell receptor recognition of CD1b presenting a mycobacterial glycolipid. Nat. Commun. 7, 13257 (2016).","journal-title":"Nat. Commun."},{"key":"1178_CR247","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00199","volume":"11","author":"K Lopez","year":"2020","unstructured":"Lopez, K. et al. CD1b tetramers broadly detect T cells that correlate with mycobacterial exposure but not tuberculosis disease state. Front. Immunol. 11, 199 (2020).","journal-title":"Front. Immunol."},{"key":"1178_CR248","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2695396","volume":"2016","author":"SA Joosten","year":"2016","unstructured":"Joosten, S. A., Sullivan, L. C. & Ottenhoff, T. H. Characteristics of HLA-E restricted T-cell responses and their role in infectious diseases. J. Immunol. Res. 2016, 2695396 (2016).","journal-title":"J. Immunol. Res."},{"key":"1178_CR249","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190834","volume":"217","author":"SC Edwards","year":"2020","unstructured":"Edwards, S. C. et al. A population of proinflammatory T cells coexpresses \u03b1\u03b2 and \u03b3\u03b4 T cell receptors in mice and humans. J. Exp. Med. 217, e20190834 (2020).","journal-title":"J. Exp. Med."},{"key":"1178_CR250","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1084\/jem.20141764","volume":"211","author":"DG Pellicci","year":"2014","unstructured":"Pellicci, D. G. et al. The molecular bases of \u03b4\/\u03b1\u03b2 T cell-mediated antigen recognition. J. Exp. Med. 211, 2599\u20132615 (2014).","journal-title":"J. Exp. Med."},{"key":"1178_CR251","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2020.36.169.21038","volume":"36","author":"MA Tolani","year":"2020","unstructured":"Tolani, M. A. et al. Acute urinary tract infection in patients with underlying benign prostatic hyperplasia and prostate cancer. Pan Afr. Med. J. 36, 169 (2020).","journal-title":"Pan Afr. Med. J."},{"key":"1178_CR252","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-01751-5","volume":"25","author":"S Lin","year":"2025","unstructured":"Lin, S. et al. The incidence and risk factors of urinary tract infections in patients undergoing bladder tumor resection: a systematic review and meta-analysis. BMC Urol. 25, 267 (2025).","journal-title":"BMC Urol."},{"key":"1178_CR253","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188520","volume":"14","author":"JW Yang","year":"2023","unstructured":"Yang, J. W., Wan, S., Li, K. P., Chen, S. Y. & Yang, L. Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma. Front. Immunol. 14, 1188520 (2023).","journal-title":"Front. Immunol."},{"key":"1178_CR254","doi-asserted-by":"publisher","first-page":"291.e1","DOI":"10.1016\/j.urolonc.2024.04.011","volume":"42","author":"J Knorr","year":"2024","unstructured":"Knorr, J. et al. An exploratory study investigating the impact of the bladder tumor microbiome on Bacillus Calmette Guerin (BCG) response in non-muscle invasive bladder cancer. Urol. Oncol. 42, 291.e1\u2013291.e11 (2024).","journal-title":"Urol. Oncol."},{"key":"1178_CR255","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.913718","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Characteristics of gut microbiota in patients with clear cell renal cell carcinoma. Front. Microbiol. 13, 913718 (2022).","journal-title":"Front. Microbiol."},{"key":"1178_CR256","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2020.07.011","volume":"78","author":"NJ Salgia","year":"2020","unstructured":"Salgia, N. J. et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur. Urol. 78, 498\u2013502 (2020).","journal-title":"Eur. Urol."},{"key":"1178_CR257","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/iid3.287","volume":"8","author":"ML Terpstra","year":"2020","unstructured":"Terpstra, M. L. et al. Circulating mucosal-associated invariant T cells in subjects with recurrent urinary tract infections are functionally impaired. Immun. Inflamm. Dis. 8, 80\u201392 (2020).","journal-title":"Immun. Inflamm. Dis."},{"key":"1178_CR258","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241287","volume":"223","author":"GR LeBlanc","year":"2026","unstructured":"LeBlanc, G. R. et al. Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. J. Exp. Med. 223, e20241287 (2026).","journal-title":"J. Exp. Med."},{"key":"1178_CR259","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01380","volume":"11","author":"J Han","year":"2020","unstructured":"Han, J. et al. Beneficial effect of antibiotics and microbial metabolites on expanded V\u03b42V\u03b39 T cells in hepatocellular carcinoma immunotherapy. Front. Immunol. 11, 1380 (2020).","journal-title":"Front. Immunol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01178-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01178-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01178-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:03:50Z","timestamp":1786453430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01178-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":259,"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01178-z","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"14 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}